Skip to main content
. 2019 Nov 4;2019:3971060. doi: 10.1155/2019/3971060

Table 2.

Reasons and time for treatment discontinuation in patients who were treated with SGLT-2 inhibitors.

Patients, N (%) Months, median (IQR)
Chronic or recurring genital yeast infections 66 (67.4) 7.5 (3-12)
Persistent or recurring urinary tract infections 11 (11.2) 6 (3-12)
Other adverse eventsa 21 (21.4) 3 (1-9)
Overall 98 (100) 6 (2-12)

aPolyuria, nausea, hypotension, dizziness, acute coronary event, worsening of glycemic control, and rapid deterioration of renal function.